BTIG Research Forecasts Strong Price Appreciation for LENSAR (NASDAQ:LNSR) Stock

LENSAR (NASDAQ:LNSR) had its price objective upped by stock analysts at BTIG Research from $7.00 to $9.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target would indicate a potential upside of 9.76% from the company’s current price.

LNSR has been the topic of a number of other research reports. Wall Street Zen cut LENSAR from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LENSAR in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, LENSAR has an average rating of “Hold” and an average target price of $11.00.

LENSAR Trading Down 0.8%

NASDAQ:LNSR opened at $8.20 on Thursday. LENSAR has a 1 year low of $4.95 and a 1 year high of $12.96. The stock has a 50-day moving average price of $5.89 and a two-hundred day moving average price of $7.37. The stock has a market cap of $100.70 million, a price-to-earnings ratio of -24.85 and a beta of 0.89.

LENSAR (NASDAQ:LNSR) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.26. The business had revenue of $16.50 million during the quarter, compared to analyst estimates of $14.65 million. LENSAR had a negative return on equity of 253.03% and a net margin of 57.57%.

Institutional Trading of LENSAR

Hedge funds have recently bought and sold shares of the business. Sanctuary Advisors LLC bought a new position in shares of LENSAR in the second quarter valued at approximately $96,000. DCF Advisers LLC bought a new stake in LENSAR during the second quarter worth $675,000. BlackRock Inc. purchased a new stake in LENSAR in the 2nd quarter valued at $1,057,000. Bank of New York Mellon Corp bought a new stake in shares of LENSAR in the 2nd quarter worth $58,000. Finally, Groupe la Francaise raised its holdings in shares of LENSAR by 16.2% in the first quarter. Groupe la Francaise now owns 213,537 shares of the company’s stock valued at $1,273,000 after purchasing an additional 29,813 shares during the last quarter. Institutional investors and hedge funds own 40.15% of the company’s stock.

Key Headlines Impacting LENSAR

Here are the key news stories impacting LENSAR this week:

• Positive Sentiment: LENSAR reported second-quarter revenue of $16.5 million, above analysts’ $14.65 million consensus estimate, and earnings of $0.10 per share versus expectations for a $0.16 loss. The results point to a significant improvement in profitability and operating performance. LENSAR Reports Second Quarter 2026 Results and Provides Business Update
• Positive Sentiment: The company placed 10 ALLY Robotic Cataract Laser Systems during the quarter, increasing its installed base to 445 systems. The ALLY backlog stood at 13 systems at June 30, suggesting continued near-term demand and potential future revenue. LENSAR signals opex to rise modestly as ALLY backlog reaches 13 systems
• Positive Sentiment: Recurring revenue reached $13.7 million, while ALLY placements grew 30%. The recurring-revenue base could improve visibility and support more consistent results as the installed system base expands. LENSAR Q2 2026 Earnings Call Highlights
• Positive Sentiment: BTIG Research raised its LENSAR price target from $7 to $9 and assigned a Buy rating, reflecting greater confidence following the earnings beat and business update.
• Neutral Sentiment: Management indicated that operating expenses will increase modestly, likely reflecting investments needed to support commercialization and the growing ALLY system base. This could temper the pace of future margin expansion.

About LENSAR

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.